Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?

Abstract

Despite the dramatic improvement in both overall survival (OS) and progression-free survival (PFS) in patients with metastatic melanoma treated with immune checkpoint inhibitors, up to 60% will develop treatment resistance and 50% will die from their disease. Therefore, although dacarbazine is no longer a mainstay of modern melanoma management, we examined the extent to, and in which context, it may still play a role. A retrospective analysis of electronic medical records of patients who had received dacarbazine treatment between October 2014 and October 2021, following innate or acquired resistance to immune checkpoint inhibitors, was performed to determine PFS and OS and examine tolerability. Nine patients with locally advanced ( n  = 1) or metastatic melanoma ( n  = 8) were identified (average age: 74 years, 4 males and 5 females). The number of cycles of dacarbazine ranged from 2 to 45 (mean = 12). One-third of patients developed a complete ( n  = 2) or partial ( n  = 1) response, two-thirds did not respond to treatment. The median PFS time was 90 days. Common adverse events included blood dyscrasias; one patient developed a grade 3 hepatitis, although it was unclear if this was due to the chemotherapy or the preceding combined immunotherapy. Dacarbazine may still be a valid option in the setting of treatment for refractory, relapsed, or progressive disease. Future studies should focus on the immunomodulatory effects of dacarbazine on the tumor microenvironment, which could be harnessed to potentially restore sensitivity to immune checkpoint-based therapy.

• Authors: Gina Klee, Victoria Hagelstein, J K Kurzhals, Detlef Zillikens, Patrick Terheyden, Ewan A Langan
• Journal: Melanoma research (Melanoma Res) Vol. 32 Issue 5 Pg. 360-365 (10 01 2022) ISSN: 1473-5636 [Electronic] England
• PMID: 35855658 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Immune Checkpoint Inhibitors
• Dacarbazine

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Dacarbazine
• Female
• Humans
• Immune Checkpoint Inhibitors
• Male
• Melanoma (pathology)
• Neoplasms, Second Primary (chemically induced)
• Retrospective Studies
• Skin Neoplasms (pathology)
• Tumor Microenvironment